An independent source of information on U.S. brand name drugs for health professionals

Drugdocs Logo

An independent source of information on U.S. brand name drugs for health professionals

HomeDrugsGlossaryAboutContact Us

Menu

HomeDrugsGlossaryAboutContact Us

Drugs A-Z

ABCDE FGHIJKLMNOPQRSTUVWXYZ

DRUGS

A

B

C

D

E

F

G

H

I

J

K

L

M

N

O

P

Q

R

S

T

U

V

W

X

Y

Z

Taltz

Chemical Nameixekizumab
Dosage FormInjection (subcutaneous; 80 mg/6 mL)
Drug ClassMonoclonal antibodies
SystemMusculoskeletal, Skin
CompanyEli Lilly and Company
Approval Year2016

Indication

  • To treat adults with moderate-to-severe plaque psoriasis.
  • To treat active ankylosing spondylitis.
  • To treat active psoriatic arthritis.
Last updated on 12/21/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Taltz (ixekizumab) Prescribing Information2019Eli Lilly and Company, Indianapolis, IN
Document TitleYearSource
CADTH common drug review clinical review report ixekizumab (Taltz) 2018CADTH
Ixekizumab for treating active psoriatic arthritis after inadequate response to DMARDs. 2018NICE
Ixekizumab for treating moderate to severe plaque psoriasis. 2017NICE
Document TitleYearSource
Adverse events with IL‐17 and IL‐23 inhibitors for psoriasis and psoriatic arthritis: a systematic review and meta‐analysis of phase III studies.2020Journal of the European Academy of Dermatology and Venereology